BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.
On January 23, 2017 the Company, on the one hand, and The
Musculoskeletal Transplant Foundation (MTF) and Hankey Capital,
LLC (Hankey Capital), on the other hand, executed an amendment
(the Amendment) to the convertible promissory notes (the
Convertible Notes) issued by the Company to each of MTF and
Hankey Capital in the principal amount of $600,000.
The Amendment extends the maturity date of each of the
Convertible Notes to December 31, 2017 from December 31, 2016. By
extending the maturity date, the date that the Convertible Notes
automatically convert into shares of the Companys Common Stock is
also extended to December 31, 2017. The Amendment is effective
retroactive to December 31, 2016.
The form of the Amendment is attached as Exhibit 10.1 to this
Report, and the summary description of the terms of the
Amendment, contained herein is qualified in its entirety by
reference to Exhibit 10.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
There is filed as part of this report the exhibit listed on the
accompanying Index to Exhibits, which information is incorporated
herein by reference.
| Exhibit No. | Description | |
| 10.1 |
Amendment to Convertible Notes with The Musculoskeletal Transplant Foundation and Hankey Capital, LLC dated as of January 23, 2017. |
About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)
Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX. BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Recent Trading Information
BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) closed its last trading session 00.00 at 1.95 with 150 shares trading hands.